We are live on ! Find out more
ESLA icon

Estrella Immunopharma
ESLA

21 hedge funds and large institutions have $29M invested in Estrella Immunopharma in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% more funds holding

Funds holding: 19 → 21 (+2)

0.49% more ownership

Funds ownership: 68.95% → 69.44% (+0.49%)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

10% less capital invested

Capital invested by funds: $32.4M → $29M (-$3.38M)

Holders
21
Holders Change
+2
Holders Change %
+10.53%
% of All Funds
0.33%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
2
Increased
2
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
+$618K
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$173K
3
OFG
OTA Financial Group
New York
+$18K
4
CH
CVI Holdings
Delaware
+$13K

Top Sellers

Rank Fund Capital Flow
1
SSA
Schonfeld Strategic Advisors
New York
-$555K
2
KIM
Karpus Investment Management
New York
-$34.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
KIM
1
Karpus Investment Management
New York
$8.62M -$34.9K -3,500 -0.4%
BFM
2
Boothbay Fund Management
New York
$3.9M – – –
HHGC
3
Hunting Hill Global Capital
New York
$2.9M – – –
Nomura Holdings
4
Nomura Holdings
Japan
$1.97M – – –
CH
5
CVI Holdings
Delaware
$1.76M +$13K +1,300 +0.7%
Hudson Bay Capital Management
6
Hudson Bay Capital Management
Connecticut
$1.75M – – –
LA
7
Linden Advisors
New York
$1.65M – – –
Goldman Sachs
8
Goldman Sachs
New York
$1.06M – – –
RCM
9
Radcliffe Capital Management
Pennsylvania
$1M – – –
PNC Financial Services Group
10
PNC Financial Services Group
Pennsylvania
$933K – – –
WA
11
Whitebox Advisors
Minnesota
$909K – – –
Citigroup
12
Citigroup
New York
$620K +$618K +62,035 New
WRBC
13
W.R. Berkley Corp
Connecticut
$543K – – –
OFG
14
OTA Financial Group
New York
$446K +$18K +1,803 +4%
PCM
15
Pinz Capital Management
New York
$241K – – –
LCM
16
Landscape Capital Management
New Jersey
$207K – – –
Janus Henderson Group
17
Janus Henderson Group
United Kingdom
$173K +$173K +17,335 New
SSA
18
Schonfeld Strategic Advisors
New York
$113K -$555K -55,687 -83%
Millennium Management
19
Millennium Management
New York
$100K – – –
WAM
20
Weiss Asset Management
Massachusetts
$100K – – –
ASM
21
ATW SPAC Management
New York
$3.9K – – –

ESLA Hedge Fund Activity: Q1 2022 in Review

21 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma (ESLA) for Q1 2022, worth a combined $29M — down 10% from $32.4M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new ESLA positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Citigroup, opening a new position worth an estimated $618K. The largest seller was Schonfeld Strategic Advisors, cutting an estimated $555K.

  • 21 institutional investors held Estrella Immunopharma (ESLA) as of Q1 2022, up from 19 in Q4 2021.
  • Funds reported $29M of Estrella Immunopharma stock for Q1 2022, down 10% quarter-over-quarter.
  • 2 funds opened new Estrella Immunopharma positions in Q1 2022 and 0 closed out, a net change of +2 holders.
  • The largest Estrella Immunopharma buyer in Q1 2022 was Citigroup, an estimated $618K added.
  • The largest Estrella Immunopharma seller in Q1 2022 was Schonfeld Strategic Advisors, an estimated $555K sold.

Based on aggregated 13F filings for Q1 2022.